Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
复制标题
DOI：
10.3390/ijms17111784
复制
发表时间：
2016-10-26
影响因子：
5.6
通讯作者：
Foj L
中科院分区：
文献类型：
--
作者：
Filella X;Foj L
前列腺特异性抗原(PSA)仍然是早期前列腺癌(PCa)治疗中最常用的生物标志物，尽管存在假阳性和过度诊断的问题。近年来，为了提高特异性和区分侵袭性和非侵袭性前列腺癌，人们提出了新的生物标志物。本文对前列腺健康指数和4KScore的新作用进行了综述。两者都是基于血液的检测，与肿瘤的侵袭性有关，这提供了遭受PCa的风险，并避免了阴性活检。此外，近年来，利用尿液作为一种非侵入性的方法来鉴定新的生物标志物，包括PCA3和TMPRSS2：ERG融合基因。现有的关于PCA3评分的结果表明，在先前阴性结果的患者中，PCA3评分在决定重复活检方面是有用的，尽管它与肿瘤侵袭性的关系存在争议。最近，不同的作者报道了前列腺癌中microRNA的异常表达。初步结果提示，循环和尿液microRNAs在PCa的检测和预后中有一定的应用价值。虽然这些新的生物标志物中有几个已经被不同的指南推荐，但有必要进行大规模的前瞻性研究和比较研究，以确定它们在PCa检测和预后中的价值。
Prostate specific antigen (PSA) remains the most used biomarker in the management of early prostate cancer (PCa), in spite of the problems related to false positive results and overdiagnosis. New biomarkers have been proposed in recent years with the aim of increasing specificity and distinguishing aggressive from non-aggressive PCa. The emerging role of the prostate health index and the 4Kscore is reviewed in this article. Both are blood-based tests related to the aggressiveness of the tumor, which provide the risk of suffering PCa and avoiding negative biopsies. Furthermore, the use of urine has emerged as a non-invasive way to identify new biomarkers in recent years, including the PCA3 and TMPRSS2:ERG fusion gene. Available results about the PCA3 score showed its usefulness to decide the repetition of biopsy in patients with a previous negative result, although its relationship with the aggressiveness of the tumor is controversial. More recently, aberrant microRNA expression in PCa has been reported by different authors. Preliminary results suggest the utility of circulating and urinary microRNAs in the detection and prognosis of PCa. Although several of these new biomarkers have been recommended by different guidelines, large prospective and comparative studies are necessary to establish their value in PCa detection and prognosis.
登录
查看更多内容
影响因子：
3.8
作者：
Benchikh A;Savage C;Cronin A;Salama G;Villers A;Lilja H;Vickers A
通讯作者：
Vickers A
影响因子：
5.2
作者：
Abd Elmageed, Zakaria Y.;Yang, Yijun;Thomas, Raju;Ranjan, Manish;Mondal, Debasis;Moroz, Krzysztof;Fang, Zhide;Rezk, Bashir M.;Moparty, Krishnarao;Sikka, Suresh C.;Sartor, Oliver;Abdel-Mageed, Asim B.
通讯作者：
Abdel-Mageed, Asim B.
影响因子：
6.6
作者：
Crawford, E. David;Rove, Kyle O.;Bostwick, David G.
通讯作者：
Bostwick, David G.
影响因子：
4.8
作者：
Donovan, M. J.;Noerholm, M.;Brown, G. A.
通讯作者：
Brown, G. A.
TMPRSS2-ERG 基因融合与临床特征和结果的关联：基于人群的前列腺癌研究的结果。
影响因子：
3.8
作者：
FitzGerald, Liesel M.;Agalliu, Ilir;Johnson, Karynn;Miller, Melinda A.;Kwon, Erika M.;Hurtado-Coll, Antonio;Fazli, Ladan;Rajput, Ashish B.;Gleave, Martin E.;Cox, Michael E.;Ostrander, Elaine A.;Stanford, Janet L.;Huntsman, David G.
通讯作者：
Huntsman, David G.